Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed solid malignancy that is metastatic or unresectable for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective.~* Subjects with brain metastases must have clinically controlled neurologic symptoms.~* Subject is able to swallow and retain oral medications and does not have uncontrolled emesis.~* Subject has adequate bone marrow, renal and hepatic function per local laboratory reference ranges.~Exclusion Criteria:~* Uncorrected serum potassium, serum magnesium, serum calcium or free thyroxin (FT4) and thyroid stimulating hormone (TSH) outside of normal reference ranges, or grade 2 hyponatremia or hypernatremia.~* Subject has severe ECG morphologic abnormalities that make QTc evaluation difficult.~* Subject has a history of cardiac conduction abnormalities.~* Subject has a significant history of cardiovascular disease.~* Subject has received any anti-cancer therapies 21 days prior to the first dose of study drug, or has recovered to no better than a grade 2 or higher clinically significant adverse effect(s)/toxicity(s) of the previous therapy.~* Use of drugs with a known risk for QT prolongation and Torsades de Pointes within 7 days prior to the first study dose.~* Use of tobacco or nicotine-containing products within 12 hours prior to the first study dose.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Sequence Group A (Type: EXPERIMENTAL): 200 mg Veliparib
- Sequence Group B (Type: EXPERIMENTAL): 400 mg Veliparib
- Sequence Group C (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).